Publications by authors named "Selim Corm"

Claim this Profile
I
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial.
Xavier Leleu, Cyrille Hulin, Jerome Lambert, Arthur Bobin, Aurore Perrot, Selim Corm

Nat Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.
Sylvain Carras, Alexia Torroja, Anouk Emadali, Emilie Montaut, Nicolas Daguindau, Selim Corm

Haematologica· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combining thrombopoietin receptor agonists with immunosuppressive drugs in adult patients with multirefractory immune thrombocytopenia, an update on the French experience.
Etienne Crickx, Mikael Ebbo, Etienne Rivière, Odile Souchaud-Debouverie, Louis Terriou, Selim Corm

Br J Haematol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vasculitis associated with myelodysplastic syndrome and chronic myelomonocytic leukemia: French multicenter case-control study.
Anne Laure Roupie, Alexis Guedon, Benjamin Terrier, Constance Lahuna, Vincent Jachiet, Sélim Corm

Semin Arthritis Rheum· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pattern of Care and Outcomes of Adolescent and Young Adults with Lymphoma Treated in the Rhône-Alpes Region.
Arthur Dony, Amine Belhabri, Yves Bertrand, Catherine Sebban, Pascale Cony-Makhoul, Selim Corm

J Adolesc Young Adult Oncol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes.
Sophie Park, Olivier Kosmider, Frédéric Maloisel, Bernard Drenou, Nicolas Chapuis, Selim Corm

Haematologica· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma.
Rémy Gressin, Nicolas Daguindau, Adrian Tempescul, Anne Moreau, Sylvain Carras, Selim Corm

Haematologica· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia.
Etienne Lengline, Bernard Drenou, Pierre Peterlin, Olivier Tournilhac, Julie Abraham, Selim Corm

Haematologica· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Paroxysmal nocturnal hemoglobinuria (PNH) and T cell large granular lymphocyte (LGL) leukemia--an unusual association: another cause of cytopenia in PNH.
Thomas Boyer, Nathalie Grardel, Marie-Christine Copin, Christophe Roumier, Aurore Touzart, Sélim Corm

Ann Hematol· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endogenous megakaryocytic colonies underline association between megakaryocytes and calreticulin mutations in essential thrombocythemia.
Julie Mondet, Ji-Hye Park, Audrey Menard, Christophe Marzac, Serge Carillo, Selim Corm

Haematologica· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Administration of alemtuzumab and G-CSF to adults with relapsed or refractory acute lymphoblastic leukemia: results of a phase II study.
Norbert-Claude Gorin, Françoise Isnard, Laurent Garderet, Souhila Ikhlef, Selim Corm

Eur J Haematol· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolites of tryptophan catabolism are elevated in sera of patients with myelodysplastic syndromes and inhibit hematopoietic progenitor amplification.
Céline Berthon, Michaela Fontenay, Selim Corm, Isabelle Briche, Delphine Allorge

Leuk Res· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents.
David Sibon, Giovanna Cannas, Fiorenza Baracco, Thomas Prebet, Norbert Vey, Selim Corm

Br J Haematol· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990-2007: a population study.
Selim Corm, Laurent Roche, Jean-Baptiste Micol, Valérie Coiteux, Nadine Bossard

Blood· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic characterization of Imatinib resistance in CD34+ cell populations from chronic myeloid leukaemia patients.
Sami Joha, Véronique Dauphin, Frédéric Leprêtre, Sélim Corm, Franck E Nicolini

Leuk Res· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial.
Carine Domenech, Xavier Thomas, Sylvie Chabaud, Andre Baruchel, François Gueyffier, Selim Corm

Br J Haematol· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.
Claude Preudhomme, Joëlle Guilhot, Franck Emmanuel Nicolini, Agnès Guerci-Bresler, Françoise Rigal-Huguet, Selim Corm

N Engl J Med· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of chronic myeloid leukaemia in clinical practice in France: results of the French subset of patients from the UNIC study.
Mauricette Michallet, Michel Tulliez, Sélim Corm, Martine Gardembas, Françoise Huguet

Curr Med Res Opin· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study.
Cecile Pautas, Fatiha Merabet, Xavier Thomas, Emmanuel Raffoux, Claude Gardin, Selim Corm

J Clin Oncol· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients' sera by HPLC and is inducible by IFN-gamma.
Selim Corm, Céline Berthon, Michel Imbenotte, Valeria Biggio, Michel Lhermitte

Leuk Res· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cryptic and partial deletions of PRDM16 and RUNX1 without t(1;21)(p36;q22) and/or RUNX1-PRDM16 fusion in a case of progressive chronic myeloid leukemia: a complex chromosomal rearrangement of underestimated frequency in disease progression?
Lauréline Deluche, Sami Joha, Sélim Corm, Agnès Daudignon, Sandrine Geffroy

Genes Chromosomes Cancer· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Guidelines for the management of dasatinib (Sprycel)-induced side effects in chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemias].
Pascale Cony-Makhoul, Anne Bergeron, Sélim Corm, Viviane Dubruille, Delphine Rea

Bull Cancer· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance.
Catherine Roche-Lestienne, Lauréline Deluche, Sélim Corm, Isabelle Tigaud, Sami Joha

Blood· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanisms of genesis of variant translocation in chronic myeloid leukemia are not correlated with ABL1 or BCR deletion status or response to imatinib therapy.
Steven Richebourg, Virginie Eclache, Christine Perot, Marie-France Portnoi, Jacqueline Van den Akker, Sélim Corm

Cancer Genet Cytogenet· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation.
Franck E Nicolini, Sandrine Hayette, Selim Corm, Emmanuel Bachy, Dominique Bories

Haematologica· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis